HIV的标准护理是需要每日口服的三种药物组合，但口服多种药物会引发顺应性问题。强生与葛兰素史克的子公司ViiV的HIV注射剂被证实提供不低于口服药物的疗效，安全性与耐受性。
ViiV Healthcare presented data from its ATLAS and FLAIR Phase III trials of its two-drug combo HIV treatment that is injected once a month. The combination was found to be non-inferior to a standard of care, daily oral three-drug combination.
葛兰素史克子公司ViiV Healthcare 提供了其 ATLAS 和 FLAIR 三期临床试验的数据，这两种药物组合 HIV 治疗每月注射一次。该组合被发现不低于标准的护理，每日口服三药组合。
ViiV’s two-drug combo is a combination of its cabotegravir and Janssen, a Johnson & Johnson company’s, Edurant (rilpivirine). The combo is injected every four weeks. The data was presented at the 2019 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Washington.
ViiV 的两种药物组合是它的卡博格韦和杨森（Janssen）的组合，后者是强生公司的 Edurant （利吡韦林）。梳子每四周注射一次。这些数据是在2019年华盛顿西雅图的逆转录病毒和机会感染会议上公布的。
“With FLAIR and ATLAS, we now have positive results from two pivotal Phase III studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily, oral three-drug regimen for the treatment of HIV,” stated John C. Pottage, Jr., ViiV’s chief scientific and medical officer. “We are also encouraged by patient preference data showing that nearly all participants who switched to the long-acting injectable regimen preferred it over their prior oral therapy.”
ViiV 首席科学和医疗官员约翰· C ·波蒂奇( John C . Pottage )说：“通过 FLAIR 和 ATLAS，我们现在从两项关键的 III 期研究中得到了积极的结果，证明这种长效的、每月一次的注射方案与每天口服的三种药物治疗 HIV 的养生法具有相似的疗效、安全性和耐受性。”“我们也对患者的偏好数据感到鼓舞，这些数据显示，几乎所有转向长效注射养生法的参与者都更喜欢这种方法，而不是之前的口服治疗。”
Often, patients prefer oral medications over receiving an injection or infusion, but daily pills sometimes result in compliance problems. In the case of this combination injection, it would, if approved, require patients to visit a clinic or physician once a month for the shot.
通常情况下，病人更喜欢口服药物而不是注射或输液，但每日的药丸有时会导致顺应性问题。在这种联合注射的情况下，如果获得批准，需要病人每月去诊所或医生看一次注射。
ATLAS, which stands for Antiretroviral Therapy as Long-Acting Suppression, had a primary endpoint of showing non-inferiority to an oral three-drug dose of two nucleoside reverse transcriptase inhibitors (NRTIs) and a third agent. The endpoint was met, with virologic suppression rates at Week 48 similar in both treatment arms.
ATLAS 是抗逆转录病毒治疗的长期抑制，它的主要终点是显示出与口服三种药物剂量的两种核苷逆转录酶抑制剂（ NRTIs ）和第三种药物的非劣效性。在48周时，两个治疗臂的病毒学抑制率相似。
閱讀更多 匯眾醫療 的文章
